DNA Link Inc Total Liabilities
DNA Link Inc total liabilities. Based on the latest financial reports, DNA Link Inc (127120) has total liabilities worth ₩53.95 Billion KRW (≈ $36.56 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are DNA Link Inc's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of DNA Link Inc (2011–2025)
Total liabilities of DNA Link Inc from 2011 to 2025. This chart illustrates how DNA Link Inc's total liabilities have evolved over time, based on quarterly financial data. Explore 127120 long-term investment intensity to see how much of total assets are deployed in long-term investments.
DNA Link Inc Competitors by Total Liabilities
The table below lists competitors of DNA Link Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alpha Hpa Ltd
AU:A4N
|
Australia | AU$103.83 Million |
|
ITAB Shop Concept AB ser. B
ST:ITAB
|
Sweden | Skr8.55 Billion |
|
Autolus Therapeutics plc
F:6A3A
|
Germany | €418.39 Million |
|
Triductor Technology (Suzhou) Inc.
SHG:688259
|
China | CN¥152.34 Million |
|
Murapol S.A.
WAR:MUR
|
Poland | zł1.79 Billion |
|
Sichuan Etrol Technologies Co Ltd
SHE:300370
|
China | CN¥779.86 Million |
|
Paslin Digital Technology Co Ltd
SHG:600215
|
China | CN¥1.32 Billion |
|
Tadiran Hldg
TA:TDRN
|
Israel | ILA1.30 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down DNA Link Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see DNA Link Inc balance sheet assets.
Liquidity & Leverage Metrics
DNA Link Inc Total Liabilities Ratios Explained
DNA Link Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how DNA Link Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for DNA Link Inc (2011–2025)
The table below shows the annual total liabilities of DNA Link Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩54.44 Billion ≈ $36.90 Million |
+85.46% |
| 2024-12-31 | ₩29.36 Billion ≈ $19.89 Million |
+135.23% |
| 2023-12-31 | ₩12.48 Billion ≈ $8.46 Million |
-20.09% |
| 2022-12-31 | ₩15.62 Billion ≈ $10.58 Million |
+89.40% |
| 2021-12-31 | ₩8.25 Billion ≈ $5.59 Million |
-40.42% |
| 2020-12-31 | ₩13.84 Billion ≈ $9.38 Million |
-14.77% |
| 2019-12-31 | ₩16.24 Billion ≈ $11.00 Million |
+5.02% |
| 2018-12-31 | ₩15.46 Billion ≈ $10.48 Million |
+996.65% |
| 2017-12-31 | ₩1.41 Billion ≈ $955.48K |
-94.14% |
| 2016-12-31 | ₩24.04 Billion ≈ $16.29 Million |
+11.69% |
| 2015-12-31 | ₩21.53 Billion ≈ $14.59 Million |
+68.92% |
| 2014-12-31 | ₩12.74 Billion ≈ $8.64 Million |
+3.34% |
| 2012-12-31 | ₩12.33 Billion ≈ $8.36 Million |
+37.43% |
| 2011-12-31 | ₩8.97 Billion ≈ $6.08 Million |
-- |
About DNA Link Inc
JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray… Read more